Thursday 19 July 2018, 13.15 – 14.30
The 64th Annual ISTH Scientific and Standardization Committee (SSC) Meeting
Wicklow Hall 2, Level 2, Convention Centre, Dublin, Ireland

Protection in Haemophilia:
The Evolving Science and Long-Term Outcomes of Fc Fusion Factors

Dear Colleague,

On behalf of Sobi™ (Swedish Orphan Biovitrum AB (publ)) and Bioverativ, a Sanofi company, we would like to invite you to the Satellite Symposium that will take place on Thursday 19 July 2018 in Wicklow Hall 2, Level 2, Convention Centre, from 13:15 – 14:30.

We look forward to seeing you at this engaging and informative scientific symposium.

With kind regards,

Stefan Lethagen (Co-Chair)    Nisha Jain (Co-Chair)
Professor, MD, PhD, Vice President
Medical Affairs, Haemophilia
Sobi™
MD, Executive Director
Medical
Bioverativ, a Sanofi company

Agenda

13:15 – 13:25 Welcome and Introduction
Stefan Lethagen, Sobi™
Nisha Jain, Bioverativ, a Sanofi company

Katalin Kis-Toth, Bioverativ, a Sanofi company

13:40 – 14:00 The Secrets of FIX Biology: Does Extravascular Distribution of FIX Matter in the Treatment of Haemophilia B?
K. John Pasi, UK

14:00 – 14:20 Raising Expectations in Haemophilia Management: Long-Term Outcomes Beyond Low ABRs
Roshni Kulkarni, USA

Questions & Answers
Faculty

14:20 – 14:30 Closing Remarks
Stefan Lethagen, Sobi™
Nisha Jain, Bioverativ, a Sanofi company
ELOCTA®: Contains efmoroctocog alfa, respectively at 250 IU (83 IU/mL); 500 IU (167 IU/mL); 1000 IU (333 IU/mL); 1500 IU (500 IU/mL); 2000 IU (667 IU/ML); 3000 IU (1000 IU/mL). Also contains 14 mg equivalent to 0.6 mmol of sodium per vial.

Indications:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ELOCTA® can be used for all age groups.

Dose and Administration: Intravenous use. Requires supervision by a physician experienced in haemophilia treatment. One IU of efmoroctocog alfa is equivalent to one IU of factor VIII in a milliliter of normal human plasma. The rate of administration should not exceed 10 mL/min.

ELOCTA®: Contains eftrenonacog alfa, respectively at 250 IU (83 IU/mL); 500 IU (167 IU/mL); 1000 IU (333 IU/mL); 1500 IU (500 IU/mL); 2000 IU (667 IU/ML); 3000 IU (1000 IU/mL). Also contains 14 mg equivalent to 0.6 mmol of sodium per vial. Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). ELOCTA® can be used for all age groups.

Date of preparation: April 2018

Sobi, Elocta and Alprolix are trademarks of Swedish Orphan Biovitrum AB (publ).

© 2018 Swedish Orphan Biovitrum AB (publ) and Bioverativ Inc – All rights reserved.

Bioverativ, a Sanofi company

Swedish Orphan Biovitrum AB (publ)
SE-112 76 Stockholm, Sweden
+46(0)8 697 20 00
www.sobi.com
PP-4039

Eloctate and Alprolix are registered trademarks of Bioverativ Therapeutics Inc.

225 Second Avenue, Waltham, MA 02451, USA
+1 781 663 4400
www.bioverativ.com

M-HEM-UK-2036